Publications
April 13, 2018 Fed. Circ. Case May Change Biosimilar IPR Strategy
February 6, 2018 U.S., European Biosimilar Approval Activity in 2017
February 1, 2018 Patent dance remains on point
December 8, 2017 Mixed Results as IPR Petitions for Biosimilars Soar
October 5, 2017 A New Strain Of Inequitable Conduct Litigation
June 6, 2017 Update on Biosimilar Approvals and Pending Applications in Europe and the U.S.
December 22, 2016 Discontent At Fed. Circ. Grows Post Cuozzo
April 27, 2016 A Breakthrough Technology is Caught in an Epic Patent Battle
March 16, 2016 Biosimilar Makers Turn To IPRs Despite Mixed Results
December 9, 2015 All Camps Agree: Memorable Biosimilar Names are a Must
October 27, 2015 TPP Biologics Exclusivity Period Maintains The Status Quo
June 2015 Biobetters: The Advantages and Challenges of Being Better
June 2015 New Targets in the Crosshairs: A forum to invalidate patents is now being used on biotech firms
April 2015 The Value of Being Highly Similar: First U.S. Biosimilar
October 2014 If High Court Reverses Teva, Litigation Costs May Increase
February 2012 FDA Issues Draft Guidelines for Biosimilars
January 2012 Partnering With The Feds For IP Enforcement: Part 1
June 2011 Supreme Court Decision: Board of Trustees of the Leland Stanford Junior University v. Roche Molecular Systems, Inc.
May 2011 IP Audits: Making the Most of Your Intellectual Property
April 9, 2010 Federal Circuit Reinvigorates the Written Description Requirement
June 2009 On Appeal Alert: Federal Circuit Grants Mandamus on Motion to Transfer Venue
Spring 2008 IP OnTrial
